Drug
Ambrisentan
Ambrisentan: highest development phase Approved, developed by Gilead Sciences, Viatris. 2 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Gilead Sciences, Viatris
Trials
| Drug | Phase | Indication |
|---|---|---|
| AMBRISENTAN | Approved | |
| ambrisentan NCT00423202 | Phase 3 | Pulmonary Arterial Hypertension |
Latest
No recent events.
Follow Ambrisentan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.